Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05013905
Registration number
NCT05013905
Ethics application status
Date submitted
13/08/2021
Date registered
19/08/2021
Date last updated
28/02/2024
Titles & IDs
Public title
A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
Query!
Scientific title
A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
Query!
Secondary ID [1]
0
0
7240-006
Query!
Secondary ID [2]
0
0
PR200-103
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
APOLLO-CD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - PRA023 IV
Treatment: Devices - Companion diagnostic (CDx)
Experimental: PRA023 - Participants to receive PRA023 administered by intravenous (IV) infusion.
Treatment: Drugs: PRA023 IV
PRA023 administered at timepoints as directed by the protocol
Treatment: Devices: Companion diagnostic (CDx)
CDx+ or CDx-
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adverse Events
Query!
Assessment method [1]
0
0
Number of participants who experienced treatment-emergent adverse events (AEs)
Query!
Timepoint [1]
0
0
Week 12
Query!
Primary outcome [2]
0
0
Serious Adverse Events
Query!
Assessment method [2]
0
0
Number of participants who experienced serious adverse events (SAEs)
Query!
Timepoint [2]
0
0
Week 12
Query!
Primary outcome [3]
0
0
Adverse Events Leading to Discontinuation
Query!
Assessment method [3]
0
0
Number of participants who experienced AEs leading to discontinuation
Query!
Timepoint [3]
0
0
Week 12
Query!
Primary outcome [4]
0
0
Endoscopic Improvement
Query!
Assessment method [4]
0
0
Number of participants achieving induction of endoscopic improvement (decrease in simple endoscopy score for Crohn's disease [SES-CD] = 50% from Baseline)
Query!
Timepoint [4]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Clinical Remission
Query!
Assessment method [1]
0
0
Number of participants achieving clinical remission, as defined by Crohn's disease activity index [CDAI] score < 150
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Endoscopic and Clinical Improvement
Query!
Assessment method [2]
0
0
Number of participants who achieved a decrease in SES-CD = 50% AND reduction in CDAI = 100 points from Baseline or CDAI<150
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Number of Participants Achieving a Composite Response
Query!
Assessment method [3]
0
0
Composite response is defined as a decrease by at least 50% in hsCRP or fecal calprotectin from baseline and a reduction of either CDAI = 100 points from Baseline or CDAI<150 in subjects with at least one elevated biomarker at baseline.
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Normalization of C-reactive Protein
Query!
Assessment method [4]
0
0
Number of participants with normalization of hsCRP (as defined by hsCRP < 5 mg/L), among subjects with elevated concentrations at Baseline, at Week 12
Query!
Timepoint [4]
0
0
Week 12
Query!
Secondary outcome [5]
0
0
Normalization of Fecal Calprotectin
Query!
Assessment method [5]
0
0
Number of participants with normalization of fecal calprotectin (fecal calprotectin < 250 ug/g), among subjects with elevated concentrations at Baseline, at Week 12
Query!
Timepoint [5]
0
0
Week 12
Query!
Secondary outcome [6]
0
0
Clinical Response
Query!
Assessment method [6]
0
0
Clinical response is defined as either a reduction of either CDAI = 100 points from Baseline or CDAI<150.
Query!
Timepoint [6]
0
0
Week 12
Query!
Secondary outcome [7]
0
0
Two Component Patient-reported Outcome (PRO-2) Remission
Query!
Assessment method [7]
0
0
Number of subjects with PRO-2 remission (defined as average daily abdominal pain score = 1 point and average daily stool frequency = 3 points with abdominal pain and stool frequency no worse than Baseline) at Week 12.
Query!
Timepoint [7]
0
0
Week 12
Query!
Secondary outcome [8]
0
0
Change From Baseline in Simple Endoscopy Score for Crohn's Disease (SES-CD)
Query!
Assessment method [8]
0
0
Assessment of change in simple endoscopy score for Crohn's Disease (SES-CD) from Baseline. Measure Description: The SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing, each on a scale from 0 (none) to 3 in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Query!
Timepoint [8]
0
0
Baseline and Week 12
Query!
Secondary outcome [9]
0
0
Serum Concentration of PRA023 (MK-7240)
Query!
Assessment method [9]
0
0
Blood samples were obtained for PK analysis of the serum concentration of PRA023 at week 12.
Query!
Timepoint [9]
0
0
Week 12
Query!
Secondary outcome [10]
0
0
Number of Participants Positive for Anti-drug Antibody (ADA)
Query!
Assessment method [10]
0
0
Blood samples were collected for the determination of anti-PR023 antibodies based on confirmatory assay. The number of participants with confirmed positive anti-PR023 antibodies results at any visit during the study is presented.
Query!
Timepoint [10]
0
0
Up to approximately 12 weeks
Query!
Secondary outcome [11]
0
0
Number of Participants With Positive Neutralizing Anti-Bodies (NAB)
Query!
Assessment method [11]
0
0
Blood samples were collected for the determination of NAB. The number of participants with positive NAB results at any visit during the study is presented.
Query!
Timepoint [11]
0
0
Up to approximately 12 weeks
Query!
Eligibility
Key inclusion criteria
- Confirmed diagnosis of Crohn's disease
- Moderately to severely active CD as defined by Crohn's disease activity index (CDAI)
score and centrally read endoscopy
- Must have corticosteroid dependence or have had no response, insufficient response,
loss of response and/or intolerance to at least one of the following therapies:
corticosteroid, immunosuppressants, or an approved anti-tumor necrosis factor (TNF),
anti-integrin, or anti-interleukin (IL)12/23
- Able to provide written informed consent and understand and comply with the
requirements of the study
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Women of child bearing potential (WOCBP) and men with female partner of childbearing
potential who are unwilling to use two highly effective methods of contraception to
avoid pregnancy for the entire study period and up to 12 weeks after the last dose of
study drug
- Diagnosis of ulcerative colitis (UC) or indeterminate colitis
- CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic
and/or illeal involvement
- Suspected or diagnosed intra-abdominal or perianal abscess at screening
- Current stoma or need for colostomy or ileostomy
- Previous small bowel resection with a combined resected length of >100 cm or previous
colonic resection of > 2 segments
- Surgical bowel resection within 3 months before screening
- Past or current evidence of definite low-grade or high-grade colonic dysplasia not
completely removed
- Subjects in the opinion of the investigator are at an unacceptable risk for
participation in the study
- Subjects who meet the protocol criteria for important laboratory exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/01/2026
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
55
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Query!
Recruitment hospital [1]
0
0
Prometheus Biosciences Selected Site - Bankstown
Query!
Recruitment hospital [2]
0
0
Prometheus Biosciences Selected Site - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Prometheus Biosciences Selected Site - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
2146 - Bankstown
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Kansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Michigan
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New Hampshire
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Texas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Washington
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Leuven
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Liège
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Ontario
Query!
Country [12]
0
0
Czechia
Query!
State/province [12]
0
0
Brno
Query!
Country [13]
0
0
Czechia
Query!
State/province [13]
0
0
Slaný
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Clichy
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Nice
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Saint-Priest-en-Jarez
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Vandœuvre-lès-Nancy
Query!
Country [18]
0
0
Georgia
Query!
State/province [18]
0
0
Tbilisi
Query!
Country [19]
0
0
Poland
Query!
State/province [19]
0
0
Kraków
Query!
Country [20]
0
0
Poland
Query!
State/province [20]
0
0
Rzeszów
Query!
Country [21]
0
0
Poland
Query!
State/province [21]
0
0
Sopot
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Torun
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Warsaw
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Wroclaw
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety and efficacy of PRA023 in participants with
moderately to severely active Crohn's Disease.
After the completion of the 12-week induction period, all participants have the option to
continue in the open-label extension for another 38 weeks.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05013905
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Prometheus Biosciences
Query!
Address
0
0
Clinicaltrials Call Center
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05013905
Download to PDF